跳转至内容
Merck
CN
所有图片(1)

主要文件

查看所有文档

安全信息

SML3137

Sigma-Aldrich

Boceprevir

≥98% (HPLC)

别名:

(1R,2S,5S)-N-[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide, (1R,5S)-N-[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide, SCH 503034, SCH503034

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C27H45N5O5
CAS号:
394730-60-0
分子量:
519.68
MDL编号:
MFCD22208555
UNSPSC代码:
12352107
NACRES:
NA.77

质量水平

100

方案

≥98% (HPLC)

表单

powder

颜色

white to beige

溶解性

DMSO: 2 mg/mL, clear

储存温度

−20°C

SMILES字符串

O=C(N1C[C@@]([H])([C@]2([C@]1(C(NC(CC3CCC3)C(C(N)=O)=O)=O)[H])[H])C2(C)C)[C@](C(C)(C)C)(NC(NC(C)(C)C)=O)[H]

InChI

1S/C27H45N5O5/c1-25(2,3)20(30-24(37)31-26(4,5)6)23(36)32-13-15-17(27(15,7)8)18(32)22(35)29-16(19(33)21(28)34)12-14-10-9-11-14/h14-18,20H,9-13H2,1-8H3,(H2,28,34)(H,29,35)(H2,30,31,37)/t15-,16?,17-,18-,20+/m0/s1

InChI key

LHHCSNFAOIFYRV-DOVBMPENSA-N

生化/生理作用

Boceprevir is an orally bioavailable, potent and selective hepatitis C virus (HCV) NS3 protease inhibitor (Ki = 14 nM; cell-based replicon assay IC50 = 350 nM).
Orally bioavailable, potent and selective hepatitis C virus (HCV) NS3 protease inhibitor.

象形图

Health hazard
GHS08

警示用语：

Warning

危险声明

H361f

危险分类

Repr. 2

储存分类代码

11 - Combustible Solids

WGK

WGK 3

法规信息

新产品

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000156203
0000156204
0000156203
0000134540
0000134540

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

B A Malcolm et al.
Antimicrobial agents and chemotherapy, 50(3), 1013-1020 (2006-02-24)
Cleavage of the hepatitis C virus (HCV) polyprotein by the viral NS3 protease releases functional viral proteins essential for viral replication. Recent studies by Foy and coworkers strongly suggest that NS3-mediated cleavage of host factors may abrogate cellular response to
Andrew J Prongay et al.
Journal of medicinal chemistry, 50(10), 2310-2318 (2007-04-21)
The structures of both the native holo-HCV NS3/4A protease domain and the protease domain with a serine 139 to alanine (S139A) mutation were solved to high resolution. Subsequently, structures were determined for a series of ketoamide inhibitors in complex with
Yanmei Hu et al.
bioRxiv : the preprint server for biology (2020-11-04)
As the COVID-19 pandemic continues to fold out, the morbidity and mortality are increasing daily. Effective treatment for SARS-CoV-2 is urgently needed. We recently discovered four SARS-CoV-2 main protease (Mpro) inhibitors including boceprevir, calpain inhibitors II and XII and GC-376
Chunlong Ma et al.
Cell research, 30(8), 678-692 (2020-06-17)
A new coronavirus SARS-CoV-2, also called novel coronavirus 2019 (2019-nCoV), started to circulate among humans around December 2019, and it is now widespread as a global pandemic. The disease caused by SARS-CoV-2 virus is called COVID-19, which is highly contagious
Xiao Tong et al.
Antiviral research, 77(3), 177-185 (2008-01-19)
An issue of clinical importance in the development of new antivirals for HCV is emergence of resistance. Several resistance loci to ketoamide inhibitors of the NS3/4A protease have been identified (residues V36, T54, R155, A156, and V170) by replicon and
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门